Celcuity
Open
$88.58
Prev. Close
$88.51
High
$88.79
Low
$88.40
Market Snapshot
$4.28B
-22.2
-2.83
155
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 155 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Celcuity, Inc. operates as a cellular analysis company. The company is headquartered in Minneapolis, Minnesota and currently employs 155 full-time employees. The company went IPO on 2017-09-20. Its lead therapeutic candidate is gedatolisib, a potent, small-molecule reversible inhibitor that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its development programs for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. A Phase III clinical trial of VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast has commenced. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells.
Recently from Cashu
Celcuity Reports Improved Loss, Focuses on Growth in Innovative Cancer Treatment Strategies
Celcuity Prepares for Future Growth Amid Recent Earnings Release Celcuity, a biotechnology firm focused on advancing cancer treatment through its innovative drug discovery platform, has recently repor…
Celcuity's Precision Medicine Strategy: Advancing Targeted Cancer Therapies for Personalized Treatment
Navigating the Landscape of Precision Medicine: Celcuity’s Strategic Focus on Cancer Therapeutics Celcuity, a clinical-stage biotechnology company, is making significant strides in the realm of precis…
Celcuity's Resilient Strategy: Innovating Cancer Therapies Amid Market Volatility
Celcuity’s Strategic Positioning Amid Market Volatility Celcuity, a biotechnology company focused on developing innovative cancer therapies, navigates a challenging economic landscape marked by height…
Celcuity's Gedatolisib Moves Closer to FDA Approval for Advanced Breast Cancer Treatment
Celcuity's Gedatolisib Advances Towards FDA Approval, Offering New Hope in Breast Cancer Treatment Celcuity Inc., a biopharmaceutical company focused on innovative cancer therapies, celebrates a pivot…